Advanced Accelerator Applications (AAA)

Oncology Corporate Profile

Company Description

Advanced Accelerator Applications (AAA) is a European pharmaceutical company founded in 2002 to develop innovative diagnostic and therapeutic products. AAA’s main focus is in the field of Molecular Imaging and targeted, individualized therapy for the management of patients with serious conditions (Personalized Medicine). AAA currently has 17 production and R&D facilities able to manufacture both diagnostics and therapeutic MNM products, and has over 290 employees in 11 countries (France, Italy, UK, Germany, Switzerland, Spain, Poland, Portugal, Israel, U.S., Canada).

Website: http://www.adacap.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Gallium-68 DOTATATEanti-cancer stem cell antibodyPancreatic neuroendocrine tumors I

View additional information on product candidates here »

Source


http://www.adacap.com

Recent News Headlines

AP Alternative Assets, L.P. Informs Investors of Availability of Additional Information Regarding Athene

11/10/2016 11:02 pm

[at noodls] - Guernsey, Channel Islands, November 10, 2016: In connection with AP Alternative Assets, L.P.'s ("AAA"; Euronext Amsterdam: AAA) equity investment in Athene Holding Ltd. ("Athene"), ...

AP Alternative Assets Informs Investors Athene to Release Third Quarter 2016 Financial Results and Host Conference Call on November 11, 2016

11/10/2016 02:04 am

[at noodls] - Guernsey, Channel Islands, November 10, 2016: In connection with AP Alternative Assets, L.P.'s ("AAA"; Euronext Amsterdam: AAA) equity investment in Athene Holding Ltd. ("Athene"), ...

AP Alternative Assets, L.P. Declares Conditional Distribution of Common Shares of Athene Holding Ltd.

11/8/2016 11:01 am

[at noodls] - Frequently Asked Questions As of November 8, 2016 INTRODUCTION The purpose of this document is to provide investors in AP Alternative Assets, L.P. ("AAA") with a set of frequently asked questions ...

Bayer Submits Supplemental New Drug Application for Stivarga® (regorafenib) for Advanced Liver Cancer

11/7/2016 06:57 am

(Bayer) Nov 7, 2016 - Bayer today announced that a supplemental New Drug Application (sNDA) for Stivarga® (regorafenib) tablets has been submitted to the U.S. Food and Drug Administration (FDA) for the second-line systemic treatment of patients with unresectable hepatocellular carcinoma (uHCC).

Novartis LEE011 (ribociclib) Granted FDA Priority Review for First-line Treatment of HR+/HER2- Advanced Breast Cancer

11/1/2016 06:59 am

(Novartis) Nov 1, 2016 - Priority Review based on Phase III MONALEESA-2 trial, which showed LEE011 plus letrozole, as initial treatment for advanced breast cancer, significantly extended progression-free survival compared to letrozole alone; underscores potential of LEE011 plus letrozole as a new treatment option for advanced breast cancer; may lead to faster access for US patients.

AP Alternative Assets Releases Financial Results for the Three and Nine Months Ended September 30, 2016

10/27/2016 11:01 pm

[at noodls] - --Net Asset Value of $39.70 per unit as of September 30, 2016-- Guernsey, Channel Islands, October 28, 2016: AP Alternative Assets, L.P. ("AAA", Euronext Amsterdam: AAA) today released its financial ...

Varian and McKesson Specialty Health Announce Strategic Agreement for Advanced Radiotherapy Equipment and Software

10/27/2016 11:51 am

(US Oncology) Oct 26, 2016 - Varian Medical Systems and McKesson Specialty Health today announced a strategic agreement for the deployment and servicing of Varian advanced radiotherapy equipment and software over a three-year period across The US Oncology Network and Vantage Oncology affiliated sites of care.

AP Alternative Assets, L.P. Informs Investors of Availability of Additional Information Regarding Athene

10/25/2016 10:04 pm

[at noodls] - Guernsey, Channel Islands, October 25, 2016: In connection with AP Alternative Assets, L.P.'s ("AAA"; Euronext Amsterdam: AAA) equity investment in Athene Holding Ltd. ("Athene"), AAA, ...

U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Patients With Advanced Form of Bladder Cancer

10/24/2016 11:43 am

(TheStreet) Oct 21, 2016 - Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration accepted a supplemental Biologics License Application, which seeks to expand the use of Opdivo to patients with locally advanced unresectable or metastatic urothelial carcinoma that has progressed on or after platinum-containing therapy.

FDA Approves Supplemental New Drug Application for XTANDI® (enzalutamide) Capsules in Advanced Prostate Cancer

10/21/2016 12:00 pm

(StreetInsider) Oct 21, 2016 - Astellas Pharma Inc.and Pfizer Inc. today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to update the U.S. product labeling for XTANDI® (enzalutamide) capsules to include new clinical data versus bicalutamide from the TERRAIN study. The data demonstrate improvement in radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (CRPC) who were treated with enzalutamide compared to patients who were treated with bicalutamide.

Merck’s KEYNOTE-045 Studying KEYTRUDA® (pembrolizumab) in Advanced Bladder Cancer (Urothelial Cancer) Meets Primary Endpoint and Stops Early

10/21/2016 07:04 am

(Merck) Oct 21, 2016 - Merck, known as MSD outside the United States and Canada, today announced that the phase 3 KEYNOTE-045 trial investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer, met the primary endpoint of overall survival (OS).

FDA Grants Accelerated Approval to New Treatment for Advanced Soft Tissue Sarcoma

10/20/2016 11:10 am

(FDA.org) Oct 19, 2016 - The U.S. Food and Drug Administration today granted accelerated approval to Lartruvo (olaratumab) with doxorubicin to treat adults with certain types of soft tissue sarcoma (STS), which are cancers that develop in muscles, fat, tendons or other soft tissues.

FDA Approves Atezolizumab for Advanced Non-Small Cell Lung Cancer

10/19/2016 11:09 am

(ASCO in Action) Oct 18, 2016 - On October 18, 2016, FDA approved atezolizumab (TECENTRIQ, Genentech Oncology) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose disease progressed during or following platinum-containing chemotherapy.

AP Alternative Assets to Release Third Quarter 2016 Financial Results on October 28, 2016

10/17/2016 02:05 pm

[at noodls] - Guernsey, Channel Islands, October 17, 2016: AP Alternative Assets, L.P. ("AP Alternative Assets" or "AAA"; Euronext Amsterdam: AAA), announced today that it plans to release its financial ...

At ESMO: One Anti-PD1 Agent Moves to the Head of the Line in Advanced NSCLC

10/15/2016 12:00 am

Pembrolizumab in front-line advanced NSCLC was a roaring success at ESMO, while nivolumab flopped, and atezolizumab proved itself as a contender by showing real benefit in second-line NSCLC. Find out what lung cancer experts had to say in Copenhagen about treating NSCLC with these checkpoint inhibitors now and in the future.

Cabozantinib Could Be First-Line Choice in Advanced RCC

10/11/2016 11:49 am

(Medscape Medical News) Oct 11, 2016 - First-line treatment of metastatic kidney cancer could be set for change, with new results showing that the oral tyrosine kinase inhibitor cabozantinib (Cabometyx, Exelixis) significantly improved disease-free survival when compared with the standard-of-care drug sunitinib (Sutent, Pfizer).

ESMO 2016 Press Release: Targeting Estrogen Receptor Improves Progression-free Survival in Advanced Breast Cancer

10/10/2016 11:59 am

(ESMO) Oct 8, 2016 - Fulvestrant significantly increases progression-free survival in women with hormone-receptor-positive advanced breast cancer, particularly those with less aggressive lower-volume disease, researchers reported at the ESMO 2016 Congress in Copenhagen.

ESMO 2016 Press Release: 70% of Advanced Cancer Patients Receive Palliative Care Consultation at ESMO Designated Centres

10/10/2016 11:22 am

(ESMO) Oct 8, 2016 - Seven out of ten patients with advanced cancer receive a palliative care consultation at ESMO Designated Centres of Integrated Oncology and Palliative Care, according to survey results reported today at the ESMO 2016 Congress in Copenhagen.

Pfizer Presents Promising New Immunotherapy Combination Data With INLYTA® (axitinib) In Advanced Renal Cell Carcinoma (RCC)

10/10/2016 10:50 am

(Pfizer) Oct 9, 2016 - Pfizer Inc. today announced data from an ongoing, investigational Phase 1b study of INLYTA® (axitinib) combined with the checkpoint inhibitor pembrolizumab (A4061079, NCT02133742), a PD-1 inhibitor known as KEYTRUDA® and marketed by Merck, known as MSD outside the United States and Canada, in treatment-naïve patients with advanced renal cell carcinoma (RCC).

Fulvestrant Demonstrates Progression-Free Survival Advantage in 1st Line Advanced Breast Cancer

10/10/2016 10:13 am

(Yahoo! Finance) Oct 8, 2016 - AstraZeneca today announced data from the Phase III FALCON trial demonstrating superior median progression-free survival (PFS) for fulvestrant 500mg compared to anastrozole 1mg in the 1st line treatment of postmenopausal women with locally-advanced or metastatic breast cancer, who have not had prior hormonal treatment for hormone receptor positive (HR+) breast cancer. The primary endpoint was PFS and the FALCON trial enrolled 462 patients.

Novartis’ Tafinlar® (dabrafenib) + Mekinist® (trametinib) Demonstrate Superior Overall Survival Benefit In Advanced Melanoma Patients At Three-Year Follow Up

10/10/2016 10:11 am

(MarketWatch) Oct 8, 2016 – Novartis today announced data from the Phase III COMBI-v study demonstrating an overall survival (OS) and a progression-free survival benefit for patients with BRAF V600 mutation-positive advanced melanoma when treated first-line with the combination of Tafinlar® (dabrafenib) + Mekinist® (trametinib) compared to vemurafenib mono therapy.

Novartis Breakthrough Therapy LEE011 Plus Letrozole Demonstrates Superior Progression-Free Survival As First-Line Treatment For Hr+/HER2- advanced Breast Cancer Compared To A Standard Of Care

10/10/2016 10:10 am

(Yahoo! Finance) Oct 8, 2016 - Results from the pivotal Phase III MONALEESA-2 study show LEE011 (ribociclib) plus letrozole significantly extended progression-free survival (PFS) compared to a standard of care, letrozole, as a first-line treatment in postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer (median PFS, 95% CI (19.3 months - not reached) vs. 14.7 months (13.0 - 16.5 months); HR=0.556; p=0.00000329)[1].

Results From CheckMate-275 Validate Further Study of Opdivo (nivolumab) in Patients With Advanced Form of Bladder Cancer

10/10/2016 09:53 am

(BMS) Oct 8, 2016 - Bristol-Myers Squibb Company announced today results from the CheckMate -275 trial, in which Opdivo had a confirmed objective response rate (ORR), the primary endpoint, of 19.6% (95% CI: 15.0 – 24.9) in platinum-refractory patients with metastatic urothelial carcinoma.

Opdivo (nivolumab) Shows Durable Response in Longest Follow-up for a PD-1 Inhibitor in Previously Treated Advanced Non-Small Cell Lung Cancer

10/10/2016 09:51 am

(BMS) Oct 9, 2016 - Bristol-Myers Squibb Company announced today updated results from two pivotal Phase 3 studies, CheckMate -057 and CheckMate -017, which showed more than one-third of previously treated metastatic non-small cell lung cancer (NSCLC) patients in both trials experienced ongoing responses with Opdivo, compared to no ongoing responses in the docetaxel arm.

Bristol-Myers Squibb Presents Results From CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) Monotherapy Versus Chemotherapy as First-Line Therapy in a Broad PD-L1 Positive Population With Advanced Lung Cancer

10/10/2016 09:50 am

(BMS) Oct 9, 2016 - Bristol-Myers Squibb Company announced today the final primary analysis of CheckMate -026, a trial investigating the use of Opdivo (nivolumab) monotherapy as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) whose tumors expressed PD-L1 ?1%.

Merck Announces Longer-Term Follow-Up of Overall Survival Data for KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma from KEYNOTE-002 Presented at ESMO 2016 Congress

10/10/2016 09:50 am

(Merck) Oct 8, 2016 - Data comparing KEYTRUDA to chemotherapy shows continued benefit with follow-up beyond 2.5 years in patients with ipilimumab-refractory advanced melanoma.

New KEYTRUDA® (pembrolizumab) Data in Advanced Urothelial Cancer Demonstrate Overall Response Rate of 24 Percent in Cisplatin-Ineligible Patients

10/10/2016 09:49 am

(Merck) Oct 8, 2016 - Results from interim analysis of phase 2 KEYNOTE-052 study to be presented at ESMO 2016 Congress and highlighted in ESMO press program; first presentation of data investigating KEYTRUDA in the front line treatment of bladder cancer.

Encouraging Results For Ribociclib In Advanced Breast Cancer

10/10/2016 06:22 am

(Forbes) Oct 9, 2016 - At the European Society for Medical Oncology (ESMO) Congress this week, investigators presented data for a new and potentially important drug, Ribociclib (Novartis). This oral medication is clearly active in hormone receptor positive (ER+ or PR+) breast cancer. The findings of the MONALEESA trial were published in the NEJM.

Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab in Advanced Genitourinary Tumors

10/7/2016 10:59 am

(Yahoo! Finance) Oct 7, 2016 - Exelixis, Inc. today announced results from a phase 1 trial of cabozantinib in combination with nivolumab in patients with previously treated genitourinary tumors.

Clovis Oncology Presents Efficacy and Safety Data From New Drug Application (NDA) Population for Rucaparib in the Treatment of Advanced Mutant BRCA Ovarian Cancer at 2016 ESMO Congress

10/7/2016 10:57 am

(Clovis) Oct 7, 2016 - Clovis Oncology announced today the oral presentation of the primary efficacy and safety data from its NDA dataset for rucaparib at the 2016 ESMO Congress in Copenhagen.

Biodesix®' VeriStrat® Test Identifies T790M-Mutated Advanced Non-Small Cell Lung Cancer Patients Who Are More Likely to Have Improved Progression-Free Survival on Third Generation EGFR-TKI Therapy

9/28/2016 12:01 pm

(Biodesix) Sept 27, 2016 - Combined results from subset analyses of the TIGER-X and TIGER-2 clinical trials show that the VeriStrat test stratifies T790M-mutated patients with previously-treated, advanced non-small cell lung cancer (NSCLC) who are more or less likely to experience longer progression-free survival (PFS) when treated with a third-generation EGFR-TKI therapy.

AP Alternative Assets, L.P. Informs Investors of Availability of Additional Information Regarding Athene

8/19/2016 09:03 pm

[at noodls] - Guernsey, Channel Islands, August 19, 2016: In connection with AP Alternative Assets, L.P.'s ("AAA"; Euronext Amsterdam: AAA) equity investment in Athene Holding Ltd. ("Athene"), AAA, ...

AP Alternative Assets Informs Investors Athene to Release Second Quarter 2016 Financial Results and Host Conference Call on August 16, 2016

8/12/2016 04:04 pm

[at noodls] - Guernsey, Channel Islands, August 12, 2016: In connection with AP Alternative Assets, L.P.'s ("AAA"; Euronext Amsterdam: AAA) equity investment in Athene Holding Ltd. ("Athene"), AAA, ...

AP Alternative Assets Releases Financial Results for the Three and Six Months Ended June 30, 2016

8/2/2016 11:01 pm

[at noodls] - --Net Asset Value of $38.60 per unit as of June 30, 2016-- Guernsey, Channel Islands, August 3, 2016: AP Alternative Assets, L.P. ("AAA", Euronext Amsterdam: AAA) today released its financial ...

AP Alternative Assets to Release Second Quarter 2016 Financial Results on August 3, 2016

7/26/2016 05:01 pm

[at noodls] - Guernsey, Channel Islands, July 26, 2016: AP Alternative Assets, L.P. ("AP Alternative Assets" or "AAA"; Euronext Amsterdam: AAA), announced today that it plans to release its financial ...

AP Alternative Assets, L.P. Informs Investors of Availability of Additional Information Regarding Athene

7/1/2016 09:04 pm

[at noodls] - Microsoft Word - AAA Athene Additional Information S-1 Amendment v1.docx Guernsey, Channel Islands, July 1, 2016: In connection with AP Alternative Assets, L.P.'s ("AAA"; Euronext Amsterdam: ...

AP Alternative Assets Informs Investors Athene to Release First Quarter 2016 Financial Results and Host Conference Call on June 16, 2016

6/15/2016 03:00 pm

[at noodls] - Microsoft Word - AAA Athene Earnings Call Announcement June 2016.doc Guernsey, Channel Islands, June 15, 2016: In connection with AP Alternative Assets, L.P.'s ("AAA"; Euronext Amsterdam: AAA) ...

AP Alternative Assets, L.P. Informs Investors of Availability of Additional Information Regarding Athene

5/19/2016 09:02 pm

[at noodls] - Microsoft Word - AAA Athene Apollo Stat Financials Update Q116.docx Guernsey, Channel Islands, May 19, 2016: In connection with AP Alternative Assets, L.P.'s ("AAA"; Euronext Amsterdam: AAA) ...

AP Alternative Assets, L.P. Informs Investors of Availability of Additional Information Regarding Athene

5/9/2016 09:04 pm

[at noodls] - Microsoft Word - AAA Athene Additional Information vFinal.docx Guernsey, Channel Islands, May 9, 2016: In connection with AP Alternative Assets, L.P.'s ("AAA"; Euronext Amsterdam: AAA) equity ...

AP Alternative Assets Informs Investors Athene to Release Fourth Quarter and Full Year 2015 Financial Results on May 9, 2016 and Host Conference Call on May 10, 2016

5/8/2016 09:04 pm

[at noodls] - Microsoft Word - Athene Earnings Call Announcement May 2016.doc Guernsey, Channel Islands, May 8, 2016: In connection with AP Alternative Assets, L.P.'s ("AAA"; Euronext Amsterdam: AAA) equity ...

AAA Informs Investors of Availability of Additional Information Regarding Athene

5/6/2016 11:04 pm

[at noodls] - Microsoft Word - Athene Additional Informationv 5.6.doc Guernsey, Channel Islands, May 6, 2016: In connection with AP Alternative Assets, L.P.'s ("AAA"; Euronext Amsterdam: AAA) equity investment ...

AP Alternative Assets Releases Financial Results for the Three Months Ended March 31, 2016

5/5/2016 12:02 am

[at noodls] - Microsoft Word - FINAL AAA Earnings Release Q1'16.docx --Net Asset Value of $32.51 per unit as of March 31, 2016-- Guernsey, Channel Islands, May 5, 2016: AP Alternative Assets, L.P. ("AAA", ...

AP Alternative Assets to Release First Quarter 2016 Financial Results on May 5, 2016

4/27/2016 03:04 pm

[at noodls] - Microsoft Word - AAA Earnings Release Announcement_2016Q1 v1.doc Guernsey, Channel Islands, April 27, 2016: AP Alternative Assets, L.P. ("AP Alternative Assets" or "AAA"; Euronext Amsterdam: ...

AP Alternative Assets Informs Investors Athene to Release Financial Results for the Year Ended December 31, 2014 and Host Conference Call on September 9, 2015

9/3/2015 10:04 pm

[at noodls] - Microsoft Word - Athene Earnings Call Announcement 9 9 15 v3.doc AP Alternative Assets Informs Investors Athene to Release Financial Results for the Year Ended December 31, 2014 and Host Conference Call ...

AP Alternative Assets, L.P. Informs Investors Athene Appoints New President

9/3/2015 08:04 pm

[at noodls] - Microsoft Word - AAA Athene Wheeler Release v2.doc Guernsey, Channel Islands, September 3, 2015: In connection with AP Alternative Assets, L.P.'s ('AAA'; Euronext Amsterdam: AAA) equity investment in Athene ...

AP Alternative Assets, L.P. Informs Investors of Availability of Additional Information Regarding Athene

8/20/2015 09:02 am

[at noodls] - Microsoft Word - AAA Athene Apollo Stat Financials Update 2Q15.docx AP Alternative Assets, L.P. Informs Investors of Availability of Additional Information Regarding Athene Guernsey, Channel Islands, August ...

AP Alternative Assets Releases Financial Results for the Three and Six Months Ended June 30, 2015

7/28/2015 11:01 pm

[at noodls] - Microsoft Word - FINAL AAA Earnings Release Q2'15.docx AP Alternative Assets Releases Financial Results for the Three and Six Months Ended June 30, 2015 --Net Asset Value of $29.90 per unit as of June ...

AP Alternative Assets to Release Second Quarter 2015 Financial Results on July 29, 2015

7/16/2015 08:03 pm

[at noodls] - Microsoft Word - AAA Earnings Release Announcement_2015Q2 v1.doc Guernsey, Channel Islands, July 16, 2015: AP Alternative Assets, L.P. ('AP Alternative Assets' or 'AAA'; Euronext Amsterdam: AAA), announced ...

AP Alternative Assets, L.P. Informs Investors Athene Appoints Interim Chief Financial Officer

7/15/2015 09:04 pm

[at noodls] - Microsoft Word - AAA Athene Interim CFO Release v1.doc AP Alternative Assets, L.P. Informs Investors Athene Appoints Interim Chief Financial Officer Guernsey, Channel Islands, July 15, 2015: In connection ...

AAA Informs Investors Athene to Release Financial Results for the Nine Months Ended September 30, 2014 and Host Conference Call on June 23, 2015

6/18/2015 11:00 pm

[at noodls] - Microsoft Word - Athene Earnings Call Announcement 6 23 15 v2.doc AAA Informs Investors Athene to Release Financial Results for the Nine Months Ended September 30, 2014 and Host Conference Call on June ...